Accurate estimation of pharmacokinetic contrast-enhanced dynamic MRI parameters of the prostate
- PMID: 11276106
- DOI: 10.1002/jmri.1085
Accurate estimation of pharmacokinetic contrast-enhanced dynamic MRI parameters of the prostate
Abstract
Quantitative analysis of contrast-enhanced dynamic MR images has potential for diagnosing prostate cancer. Contemporary fast acquisition techniques can give sufficiently high temporal resolution to sample the fast dynamics observed in the prostate. Data reduction for parametric visualization requires automatic curve fitting to a pharmacokinetic model, which to date has been performed using least-squares error minimization methods. We observed that these methods often produce unexpectedly noisy estimates, especially for the typically fast, intermediate parameters time-to-peak and start-of-enhancement, resulting in inaccurate pharmacokinetic parameter estimates. We developed a new curve fit method that focuses on the most probable slope. A set of 10 patients annotated using histopathology was used to compare the conventional and new methods. The results show that our new method is significantly more accurate, especially in the relatively less-enhancing peripheral zone. We conclude that estimation accuracy depends on the curve fit method, which is especially important when evaluating the peripheral zone of the prostate.
Similar articles
-
Robust and efficient pharmacokinetic parameter non-linear least squares estimation for dynamic contrast enhanced MRI of the prostate.Magn Reson Imaging. 2018 May;48:50-61. doi: 10.1016/j.mri.2017.12.021. Epub 2017 Dec 24. Magn Reson Imaging. 2018. PMID: 29278764 Free PMC article.
-
Dynamic contrast enhanced MRI of the prostate: comparison of gadobutrol and Gd-DTPA.Rofo. 2013 Sep;185(9):862-8. doi: 10.1055/s-0033-1335892. Epub 2013 Jul 25. Rofo. 2013. PMID: 23888476
-
Analysis of prostate DCE-MRI: comparison of fast exchange limit and fast exchange regimen pharmacokinetic models in the discrimination of malignant from normal tissue.Invest Radiol. 2009 Sep;44(9):577-84. doi: 10.1097/RLI.0b013e3181b4c1fe. Invest Radiol. 2009. PMID: 19668002
-
Dynamic contrast-enhanced magnetic resonance imaging in the evaluation of the prostate.Top Magn Reson Imaging. 2008 Dec;19(6):273-84. doi: 10.1097/RMR.0b013e3181aacdc2. Top Magn Reson Imaging. 2008. PMID: 19512849 Review.
-
Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters.AJR Am J Roentgenol. 2007 Oct;189(4):849. doi: 10.2214/AJR.06.1329. AJR Am J Roentgenol. 2007. PMID: 17885055
Cited by
-
Automated Quantitative Analysis of CT Perfusion to Classify Vascular Phenotypes of Pancreatic Ductal Adenocarcinoma.Cancers (Basel). 2024 Jan 30;16(3):577. doi: 10.3390/cancers16030577. Cancers (Basel). 2024. PMID: 38339328 Free PMC article.
-
Volumetric and Voxel-Wise Analysis of Dominant Intraprostatic Lesions on Multiparametric MRI.Front Oncol. 2019 Jul 5;9:616. doi: 10.3389/fonc.2019.00616. eCollection 2019. Front Oncol. 2019. PMID: 31334128 Free PMC article.
-
[Imaging for initial diagnosis of localized prostate cancer].Urologe A. 2019 May;58(5):494-503. doi: 10.1007/s00120-019-0901-x. Urologe A. 2019. PMID: 30874832 Review. German.
-
Habitats in DCE-MRI to Predict Clinically Significant Prostate Cancers.Tomography. 2019 Mar;5(1):68-76. doi: 10.18383/j.tom.2018.00037. Tomography. 2019. PMID: 30854444 Free PMC article.
-
Predicting clinically significant prostate cancer using DCE-MRI habitat descriptors.Oncotarget. 2018 Dec 14;9(98):37125-37136. doi: 10.18632/oncotarget.26437. eCollection 2018 Dec 14. Oncotarget. 2018. PMID: 30647849 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical